AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancersFORT MYERS, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented ...

Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial ...

Imugene announces phase 1b trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma: Sydney Wednesday, July 16, 2025, 15:30 Hrs [IST] Imugene L ...

FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in ...

Glofitamab is a bispecific CD20-directed CD3 T-cell engager approved under the brand name Columvi ® for the treatment of adults with R/R DLBCL, not otherwise specified or large B-cell lymphoma arising ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

The Badgers had three players selected in the 2025 NHL Draft, two of them by a team that now holds four Wisconsin prospects.